Acumen Pharmaceuticals, Inc.
$2.29
-0.65%Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.1).
Valuation inputs: P/E -1.1, earnings yield N/A, momentum -0.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.7%, ROIC -1.2%).
Profitability stack: net margin 0.0%, ROE -1.7%, ROIC -1.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +42.7%, momentum -0.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Acumen Pharmaceuticals, Inc. Market vs Earnings Trajectory
Performance Analysis
EPS Growth
Positive earnings growth shows the company is improving its profitability over time.
Price-EPS Relationship
Stock price is moving in line with earnings growth—a healthy sign of fundamental-driven valuation.
Stock Price Change
Over the 1Y period, stock price has increased by 114.0%.
P/E Ratio (TTM)
Relatively low P/E may indicate undervaluation or lower growth expectations.
Key Insight
Stock price (+114.0%) is outpacing earnings growth (+18.0%), suggesting the market may be pricing in future growth. Monitor if earnings can catch up to justify the valuation.
Acumen Pharmaceuticals, Inc. Fair Value Envelope
Acumen Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Acumen Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Acumen Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Acumen Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that ABOS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 7.00, with estimates ranging from a low of 7.00 to a high of 7.00.
The consensus 1-year price target stands at 7.00, with estimates ranging from a low of 7.00 to a high of 7.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Acumen Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $116K and sold $220K worth of ABOS shares, resulting in $105K of net selling activity.
3 Months
0
0.00
2.1K
6.81K
-7K
-$7K
3-6 Months
0
0.00
98.0K
213.60K
-214K
-$214K
6-9 Months
50.0K
95.00K
0
0.00
+95K
+$95K
9-12 Months
19.5K
20.86K
0
0.00
+21K
+$21K
Top Buyers
Golumbeski George
Director
$95K
Stalfort John A Iii
Director
$21K
Top Sellers
Meisner Derek M
Officer: Chief Legal Officer & Corp Sec
$118K
Zuga Matt
Officer: Cfo & Chief Business Officer
$46K
Oconnell Daniel Joseph
Director, Officer: Chief Executive Officer
$22K
Doherty James J.
Officer: President And Cdo
$15K
Barton Russell
Officer: Chief Operating Officer
$12K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $105K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
ABOS has not reported any dividend yield values in the available annual periods.
abos Dividend History
Learning Layer
Related Guides
Build conviction on ABOS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.